184 related articles for article (PubMed ID: 35767226)
1. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer.
Watson NW; Wander SA; Shatzel JJ; Al-Samkari H
Cancer; 2022 Sep; 128(17):3224-3232. PubMed ID: 35767226
[TBL] [Abstract][Full Text] [Related]
2. CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice.
West MT; Smith CE; Kaempf A; Kohs TCL; Amirsoltani R; Ribkoff J; Choung JL; Palumbo A; Mitri Z; Shatzel JJ
Eur J Haematol; 2021 May; 106(5):634-642. PubMed ID: 33527479
[TBL] [Abstract][Full Text] [Related]
3. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review.
Gao S; Li Y; He Z; Zhu J; Liang D; Yang S; Mo J; Lam K; Yu X; Huang M; Wu J
Expert Opin Drug Saf; 2023; 22(7):599-609. PubMed ID: 36794339
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Gervaso L; Montero AJ; Jia X; Khorana AA
J Thromb Haemost; 2020 Jan; 18(1):162-168. PubMed ID: 31479568
[TBL] [Abstract][Full Text] [Related]
5. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 4/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence.
Watson NW; Shatzel JJ; Al-Samkari H
J Thromb Haemost; 2023 Apr; 21(4):758-770. PubMed ID: 36696184
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials.
Thein KZ; Htut TW; Ball S; Swarup S; Sultan A; Oo TH
Breast Cancer Res Treat; 2020 Sep; 183(2):479-487. PubMed ID: 32647939
[TBL] [Abstract][Full Text] [Related]
8. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.
Badaoui S; Kichenadasse G; Rowland A; Sorich MJ; Hopkins AM
Oncologist; 2021 Jul; 26(7):562-568. PubMed ID: 33914991
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
[TBL] [Abstract][Full Text] [Related]
12. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
Xu X; Chlebowski RT; Shi J; Barac A; Haque R
Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
[TBL] [Abstract][Full Text] [Related]
13. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer.
Cuyun Carter G; Sheffield KM; Gossai A; Huang YJ; Zhu YE; Bowman L; Nash Smyth E; Mathur R; Cohen AB; Rasmussen E; Balakrishna S; Morato Guimaraes C; Rybowski S; Seidman AD
Curr Med Res Opin; 2021 Jul; 37(7):1179-1187. PubMed ID: 33970738
[TBL] [Abstract][Full Text] [Related]
14. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
15. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC.
Al-Samkari H; Leiva O; Dagogo-Jack I; Shaw A; Lennerz J; Iafrate AJ; Bendapudi PK; Connors JM
J Thorac Oncol; 2020 Sep; 15(9):1497-1506. PubMed ID: 32437899
[TBL] [Abstract][Full Text] [Related]
16. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
Palumbo A; Lau G; Saraceni M
Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
18. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
[TBL] [Abstract][Full Text] [Related]
19. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
